Moore, Kathleen N <br/><br/>
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.  [electronic resource] 

 -  Cancer  Dec 2010 
 - 5407-14 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.25480  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibiotics, Antineoplastic--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Clinical Trials, Phase III as Topic<br/>Disease-Free Survival<br/>Doxorubicin--therapeutic use<br/>Endometrial Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Middle Aged<br/>Randomized Controlled Trials as Topic<br/>Recurrence<br/>Salvage Therapy<br/>Survival Analysis<br/>Time Factors